Mamadou Kaba is a clinician-scientist from Guinea. Some of his works has led to practical changes in health policies. He is currently a Principal Investigator and the Director of the African Microbiome and Epidemiology Research Group (AfriMERG) at the University of Cape Town, South Africa. He is the primary supervisor of five African (from Ghana, Kenya, Namibia, South Africa and Zimbabwe) postgraduate students (4 MSc and 1 PhD) working on microbiome related-projects. His research interests include studying the role of microbes in the development and/or response to treatment of childhood asthma, diabetes, cancers and sickle cell disease. These diseases are united by Mamadou’s desire to contribute in improving the health of the African populations. Mamadou has received research grants from the Wellcome Trust (United Kingdom), the CIHR Canadian HIV Trials Network (Canada), the Carnegie Corporation of New York (USA) and the National Institutes of Health (USA).

Mamadou Kaba is a clinician-scientist from Guinea. Some of his works has led to practical changes in health policies. He is currently a Principal Investigator and the Director of the African Microbiome and Epidemiology Research Group (AfriMERG) at the University of Cape Town, South Africa. He is the primary supervisor of five African (from Ghana, Kenya, Namibia, South Africa and Zimbabwe) postgraduate students (4 MSc and 1 PhD) working on microbiome related-projects. His research interests include studying the role of microbes in the development and/or response to treatment of childhood asthma, diabetes, cancers and sickle cell disease. These diseases are united by Mamadou’s desire to contribute in improving the health of the African populations. Mamadou has received research grants from the Wellcome Trust (United Kingdom), the CIHR Canadian HIV Trials Network (Canada), the Carnegie Corporation of New York (USA) and the National Institutes of Health (USA).